Search for content, post, videos
Advertisement

AlzeCure’s Alzheimer’s project granted an additional patent

AlzeCure Pharma has announced that the patent offices in China, India, South Africa, Israel, Hong Kong and Mexico have granted patents covering the company’s clinical drug candidate ACD856, which is being developed against Alzheimer’s and other disorders with cognitive impairment.

“This further strengthens the patent portfolio for ACD856 and is an important part of our continued strategic patent work with the NeuroRestore program where the goal is to build global IP protection for the molecule,” says Gunnar Nordvall, Head of Chemistry and IP på AlzeCure Pharma.

The patents are expected to provide protection until 2039. Previously, ACD856 has been granted patent protection in the USA, Japan and Europe.

ACD856

ACD856 and other substances in the NeuroRestore platform stimulate several important signaling systems and signaling molecules in the brain such as BDNF (Brain Derived Neurotrophic Factor) and NGF (Nerve Growth Factor), which can lead to improved cognition. Previous preclinical studies have shown that AlzeCure’s drug candidates strengthen communication between nerve cells and improve cognitive ability, including learning and memory functions.

AlzeCure completed phase I clinical studies with ACD856 in 2022, where both good safety and tolerability were demonstrated in humans, but also that the drug candidate crossed the blood-brain barrier and that the substance activated parts of the brain that are central to both cognition and depression treatment. New preclinical results also show potential neuroprotective and disease-modifying effects with these substances, which can be very significant for the project.

Photo of Martin Jönsson: Jenny Lagerqvist

Advertisement